Therapeutics News and Research

RSS

Oral molecule prevents kidney stones and restores survival in mice

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones, protect against kidney failure, and fully restore normal survival in a mouse model of Primary Hyperoxaluria Type 2 (PH2), a rare and currently untreatable genetic disorder that causes progressive kidney failure in infants and young adults.

2 Apr 2026

Northumbria University spinout earns CE mark for breath sampling device

A medical device company spun out of Northumbria University has reached a significant milestone — receiving CE marking for a breath sampling platform that peer-reviewed research has demonstrated can reliably collect saliva-free exhaled breath condensates (EBC) from the deep lung, making it the first technology of its type to achieve this distinction.

2 Apr 2026

New dual drugs eliminate tumors when combined with immunotherapy

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.

2 Apr 2026

Researchers develop low-cost scalable sensors to study genetic brain disorders

Researchers have demonstrated a new class of low-cost, scalable sensors that can be used to monitor electrical activity in human cerebral organoids.

2 Apr 2026

Popular vitamin B3 supplements could weaken cancer therapy effectiveness

Millions of Americans take daily supplements-nicotinamide mononucleotide (NMN), nicotinamide riboside (NR) and nicotinamide (NAM)-to boost energy, slow aging and protect the heart and brain.

1 Apr 2026

"Smart" system distinguishes and neutralizes cancer cells with unprecedented precision

A team from UNIGE has designed a molecular system that distinguishes and neutralizes cancer cells with unprecedented precision, paving the way for autonomous, self-regulating drugs.

1 Apr 2026

Gut bacteria determine fiber benefits in celiac disease patients

Many people with celiac disease are advised to eat more fiber to support digestion and manage symptoms, either through diet or prescribed fiber supplements.

31 Mar 2026

How the nutrient cysteine controls cancer-fighting power of T cells

A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Bloomberg School of Public Health have discovered how the immune system's CD8+ T cells use the nutrient cysteine to control two essential functions that compete for this resource - the immune cell's ability to multiply and its ability to kill cancer cells.

31 Mar 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Antibiotic resistance genes found in both diseased and healthy lungs

The researchers examined patients with COPD, asthma, pulmonary fibrosis (IPF), and sarcoidosis, and compared them with healthy individuals.

31 Mar 2026

How gut imbalance may drive obesity, diabetes, and heart disease

A new review argues that gut dysbiosis is closely linked to metabolic dysfunction through intertwined effects on inflammation, oxidative stress, gut barrier integrity, microbial metabolites, and epigenetic regulation. It also highlights microbiome-targeted strategies such as high-fiber diets, probiotics, prebiotics, postbiotics, exercise, and fecal microbiota transplantation as promising ways to support metabolic health.

30 Mar 2026

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

30 Mar 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

Study reveals ALDH2 vulnerability in APC-deficient colorectal cancer

A precision cancer strategy that selectively kills tumour cells while leaving healthy tissue intact may be within reach for the majority of colorectal cancer patients, according to new research published in Genes & Disease.

30 Mar 2026

Brain pathway explains how stress drives alcohol-seeking behavior

Why do stressful moments so often push people toward habits like drinking? A new study from Texas A&M University offers one of the clearest answers yet, identifying a direct connection inside the brain that links stress to addiction‑related behaviors.

30 Mar 2026

Red blood cell exchange transfusion may provide benefits for patients with severe babesiosis

A new study led by investigators from Mass General Brigham and Yale School of Public Health reveals that red blood cell exchange transfusion (ET) may provide critical benefits for patients hospitalized with severe babesiosis.

30 Mar 2026

Mount Sinai researchers identify a highly prevalent recessive neurodevelopmental disorder

Researchers at the Icahn School of Medicine at Mount Sinai in New York have identified and described a previously unknown recessive neurodevelopmental disorder (NDD) that appears to be the most prevalent ever discovered.

30 Mar 2026

CFHR1 could be a new diagnostic marker for IgA nephropathy

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial cell proliferation, enhanced extracellular matrix production, and variable infiltration of inflammatory cells.

30 Mar 2026

Hypercortisolism found in many patients with resistant hypertension

The MOMENTUM study found 27 percent of patients with resistant hypertension have hypercortisolism. This is a significant finding, demonstrating that hypercortisolism is more common in these patients than previously understood by researchers and clinicians.

28 Mar 2026

Gut immune responses found to trigger brain inflammation in MS

Multiple sclerosis (MS) is a debilitating neurological disorder caused by malfunctioning immune responses that target the brain and spinal cord of the central nervous system (CNS).

27 Mar 2026